查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
镰状细胞疾病 (SCD) 治疗的全球市场：市场规模、占有率、成长分析、治疗类型、最终用户 - 产业预测，2023-2030 年
市场调查报告书
商品编码
1396147

镰状细胞疾病 (SCD) 治疗的全球市场：市场规模、占有率、成长分析、治疗类型、最终用户 - 产业预测，2023-2030 年

Global Sickle Cell Disease Treatment Market Size, Share, Growth Analysis, By Treatment type(Pharmaceuticals and supportive care), By End user(Hospitals, clinics) - Industry Forecast 2023-2030
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2021年镰状细胞疾病（SCD）治疗市场规模为17.3亿美元，将从2022年的21亿美元成长到2030年的99亿美元，预测期间（2023-2030年）复合年增长率为21.4% 。预计将增长至1000万美元。

全球镰状细胞疾病（SCD）治疗市场是一个充满活力且重要的市场，用于满足镰状状细胞疾病（SCD）患者的医疗需求。镰状细胞疾病（SCD）是一种遗传性血液疾病，其特征是血红蛋白异常，导致红血球变得僵硬并呈新月形，导致多种併发症和健康问题。该市场旨在开发创新治疗方法、药物和支持性护理，以提高 SCD 患者的生活品质。镰状细胞疾病（SCD）在世界各地的高盛行率，特别是在撒哈拉以南非洲、中东和亚洲的某些地区，迫切需要有效的治疗方法。我强调这一点。

医学研究的进步，包括基因治疗和标靶药物开发，正在为创新治疗方法开闢新途径。此外，人们对 SCD 及其影响的认识不断提高，以及政府的配合措施和支持，正在推动研发投资。然而，也存在一些限制，特别是在低收入地区，例如医疗资源有限，阻碍了有效的诊断和治疗。与先进治疗方法相关的高成本和有限的报销选择可能会阻碍市场成长。该疾病的复杂性和对个体化治疗方法的需求增加了医疗保健提供者和研究人员面临的挑战。主要市场趋势包括精准医疗的兴起和针对每位患者基因特征个体化治疗方案。製药公司、研究机构和倡导团体之间的合作在追求创新治疗方法方面越来越受到关注。市场开拓机会在于扩大服务欠缺地区的医疗保健覆盖范围、开发具有成本效益的治疗方法以及探索基因编辑和干细胞移植等新治疗方法。随着研发投资的增加、技术的进步以及对改善患者治疗结果的关注，全球市场对于製药公司、生物技术公司和医疗保健提供者来说变得越来越重要，以解决SCD 患者未得到满足的需求。我们提供这是一个令人兴奋的机会，可以对我们的应对措施产生重大影响。透过利用创新、协作和以患者为中心的方法的力量，这个市场有潜力改变数百万人遭受这项挑战的生活。

本报告的目标细分市场

全球镰状细胞疾病（SCD）治疗市场根据治疗类型、最终用户和地区进行细分。依治疗类型，市场分为药物和支持性护理。依最终用户划分，市场分为医院、诊所、研究机构等。依地区划分，分为北美、欧洲、亚太地区、中东/非洲、拉丁美洲。

促进因素

基因治疗的进展

使用基因疗法作为治疗镰状细胞疾病（SCD）的有前景的方法已经取得了重大进展。 CRISPR-Cas9 等基因编辑技术的出现为纠正导致镰状细胞疾病 (SCD) 的潜在基因突变开闢了新途径。 2020年，美国食品药物管理局（FDA）核准了第一个针对SCD的基因疗法Zynteglo。这种创新治疗方法修改患者自身的干细胞以产生健康的血红蛋白，从而减轻疾病的症状。基因疗法的这些进展为镰状细胞疾病（SCD）更有效、更持久的治疗带来了希望。

抑制因素

医疗资源取得受限

儘管医学取得了进步，但在确保获得优质卫生服务方面仍然存在重大挑战，特别是在镰状细胞疾病（SCD）流行的低收入地区。基础设施不足、缺乏卫生设施以及缺乏训练有素的专业人员阻碍了镰状细胞疾病 (SCD) 的有效诊断和治疗。获得医疗保健资源的机会有限会导致诊断延迟、併发症管理不善以及患者治疗效果不佳。为了向镰状细胞疾病（SCD）患者提供及时、适当的医疗护理，必须解决医疗资源短缺的问题并加强医疗基础设施。

市场趋势：

个人化医疗与精准治疗

镰状细胞疾病 (SCD) 治疗的一个显着趋势是越来越重视个人化医疗。基因检测和识别与镰状细胞疾病 (SCD) 相关的个体遗传变异的进步正在促进量身定制的治疗方法。例如，FDA核准用于治疗 SCD 的羟基脲已被证明在不同患者中具有不同的反应。正在进行的研究和开发正在积极识别预测治疗反应的生物标记和遗传因素，为开发旨在改善治疗结果的个体化治疗方法铺平道路。

目录

  • 执行摘要
  • 调查方法
  • 母市场分析
  • 主要市场考察
    • 技术分析
    • 价格分析
    • 供应链分析
    • 价值链分析
    • 市场生态系统
    • 智慧财产权分析
    • 贸易分析
    • Start-Ups分析
    • 原料分析
    • 创新矩阵
    • 研发线产品分析
    • 总体经济指标
    • 主要投资分析
    • 关键成功因素
    • 竞争程度
  • 市场动态及展望
    • 市场动态
      • 促进因素
      • 机会
      • 抑制因素
      • 任务
    • 监管形势
    • 波特的分析
    • 对未来中断的特殊考察
  • 镰状细胞疾病 (SCD) 治疗的全球市场：依治疗类型
    • 市场概况
    • 药物和支持性护理
  • 镰状细胞疾病 (SCD) 治疗的全球市场：按最终用户划分
    • 市场概况
    • 医院
    • 诊所
    • 研究机构
    • 其他的
  • 按地区分類的全球镰状细胞疾病 (SCD) 治疗市场规模
    • 市场概况
    • 北美洲
      • 美国
      • 加拿大
    • 欧洲
      • 德国
      • 西班牙
      • 法国
      • 英国
      • 其他欧洲国家地区
    • 亚太地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 其他亚太地区
    • 拉丁美洲
      • 巴西
      • 其他拉丁美洲地区
    • 中东和非洲 (MEA)
      • 海湾合作委员会国家
      • 南非
      • 其他中东/非洲地区
  • 竞争形势
    • 前5名企业对比
    • 主要企业市场定位（2021年）
    • 主要市场参与者所采取的策略
    • 关键成功策略
    • 近期市集活动
    • 主要企业市场占有率（2021年）
  • 主要企业简介
    • Novartis（Switzerland）
    • Pfizer（US）
    • Global Blood Therapeutics（US）
    • Bluebird Bio（US）
    • Bristol Myers Squibb（US）
    • Sangamo Therapeutics（US）
    • Emmaus Life Sciences（US）
    • Eli Lilly and Company（US）
    • Modus Therapeutics（Sweden）
    • Gamida Cell（Israel）
    • Lonza Group（Switzerland）
    • Addmedica（France）
    • Selexys Pharmaceuticals（US）
    • GlycoMimetics（US）
    • Mast Therapeutics（US）
    • Acceleron Pharma（US）
    • Angiocrine Bioscience（US）
    • Imara Inc.（US）
    • AstraZeneca（UK）
    • Sanofi（France）
简介目录
Product Code: SQMIG35D2091

Sickle Cell Disease Treatment Market size was valued at USD 1.73 billion in 2021 and is poised to grow from USD 2.10 billion in 2022 to USD 9.91 billion by 2030, at a CAGR of 21.4% during the forecast period (2023-2030).

The Global Sickle Cell Disease Treatment Market is a dynamic and essential sector dedicated to addressing the medical requirements of individuals afflicted with sickle cell disease (SCD). SCD is a genetic blood disorder characterized by abnormal hemoglobin, leading to the deformation of red blood cells into rigid and crescent shapes, resulting in various complications and health issues. The market aims to develop innovative therapies, medications, and supportive care options to enhance the quality of life for individuals affected by SCD. The high prevalence of sickle cell disease globally, particularly in sub-Saharan Africa, the Middle East, and specific regions of Asia, underscores the pressing need for effective treatments.

Advancements in medical research, including gene therapy and targeted drug development, have opened new avenues for innovative treatment approaches. Additionally, increasing awareness about SCD and its impact, along with government initiatives and support, has fueled investments in research and development. Nevertheless, the market faces constraints such as limited access to healthcare resources, especially in low-income regions, hindering effective diagnosis and treatment. The high costs associated with advanced therapies and limited reimbursement options can impede market growth. The complex nature of the disease and the necessity for personalized treatment approaches contribute to the challenges faced by healthcare providers and researchers. Key trends in the market include the emergence of precision medicine and personalized treatment options tailored to individual patients' genetic profiles. Collaborations between pharmaceutical companies, research institutions, and advocacy groups have gained prominence in the pursuit of innovative therapies. Opportunities in the market lie in expanding access to healthcare in underserved regions, developing cost-effective treatments, and exploring novel therapeutic modalities such as gene editing and stem cell transplantation. With increasing investments in research and development, advancements in technology, and a growing focus on improving patient outcomes, the global market presents an attractive opportunity for pharmaceutical companies, biotechnology firms, and healthcare providers to make a significant impact in addressing the unmet needs of individuals living with SCD. By harnessing the power of innovation, collaboration, and patient-centric approaches, the market holds the potential to transform the lives of millions affected by this challenging disease.

Segments covered in this report

Global Sickle Cell Disease Treatment Market is segmented on the basis of treatment type, end user, and region. By treatment type, the market is segmented into pharmaceuticals and supportive care. By end user, the market is segmented into hospitals, clinics, research institutes, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers:

Advancements in Gene Therapy

Significant progress has been made in utilizing gene therapy as a promising approach for treating sickle cell disease. The advent of gene-editing technologies, such as CRISPR-Cas9, has opened new avenues for correcting the underlying genetic mutation responsible for SCD. In 2020, the U.S. Food and Drug Administration (FDA) approved Zynteglo, the first gene therapy for SCD. This innovative therapy involves modifying a patient's own stem cells to produce healthy hemoglobin, thereby reducing the symptoms of the disease. These advancements in gene therapy provide hope for more effective and enduring treatments for sickle cell disease.

Restraints

Limited Access to Healthcare Resources

Despite the strides in medical advancements, significant challenges persist in ensuring access to quality healthcare services, particularly in low-income regions where sickle cell disease is prevalent. Inadequate infrastructure, a shortage of healthcare facilities, and a lack of trained professionals impede the effective diagnosis and treatment of SCD. The limited access to healthcare resources contributes to delayed diagnosis, insufficient management of complications, and suboptimal patient outcomes. Addressing these resource gaps and enhancing healthcare infrastructure are essential to ensuring timely and appropriate care for individuals affected by sickle cell disease.

Market Trends:

Personalized Medicine and Precision Therapies

A noticeable trend in the management of sickle cell disease (SCD) is the increasing emphasis on personalized medicine. Progress in genetic testing and the comprehension of individual genetic variations linked to SCD have facilitated the adoption of tailored treatment approaches. For example, hydroxyurea, an FDA-approved medication for SCD, has exhibited varying responses among patients. Ongoing research is actively identifying biomarkers and genetic factors to predict treatment responses, paving the way for the development of personalized treatment regimens that aim for enhanced outcomes.

Table of Contents

  • Executive Summary
    • Market Overview
    • Wheel of Fortune
  • Research Methodology
    • Information Procurement
    • Secondary & Primary Data Sources
    • Market Size Estimation
    • Market Assumptions & Limitations
  • Parent Market Analysis
    • Market Overview
    • Market Size
    • Market Dynamics
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Key Market Insights
    • Technology Analysis
    • Pricing Analysis
    • Supply Chain Analysis
    • Value Chain Analysis
    • Ecosystem of the Market
    • IP Analysis
    • Trade Analysis
    • Startup Analysis
    • Raw Material Analysis
    • Innovation Matrix
    • Pipeline Product Analysis
    • Macroeconomic Indicators
    • Top Investment Analysis
    • Key Success Factor
    • Degree of Competition
  • Market Dynamics & Outlook
    • Market Dynamics
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
    • Regulatory Landscape
    • Porters Analysis
      • Competitive rivalry
      • Threat of Substitute Products
      • Bargaining Power of Buyers
      • Threat of New Entrants
      • Bargaining Power of Suppliers
    • Skyquest Special Insights on Future Disruptions
      • Political Impact
      • Economic Impact
      • Social Impact
      • Technical Impact
      • Environmental Impact
      • Legal Impact
  • Global Sickle Cell Disease Treatment Market by Treatment type
    • Market Overview
    • Pharmaceuticals and supportive care
  • Global Sickle Cell Disease Treatment Market by End user
    • Market Overview
    • Hospitals
    • clinics
    • research institutes
    • and others
  • Global Sickle Cell Disease Treatment Market Size by Region
    • Market Overview
    • North America
      • USA
      • Canada
    • Europe
      • Germany
      • Spain
      • France
      • UK
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia-Pacific
    • Latin America
      • Brazil
      • Rest of Latin America
    • Middle East & Africa (MEA)
      • GCC Countries
      • South Africa
      • Rest of MEA
  • Competitive Landscape
    • Top 5 Player Comparison
    • Market Positioning of Key Players, 2021
    • Strategies Adopted by Key Market Players
    • Top Winning Strategies
      • By Development
      • By Company
      • By Year
    • Recent Activities in the Market
    • Key Companies Market Share (%), 2021
  • Key Company Profiles
    • Novartis (Switzerland)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Pfizer (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Global Blood Therapeutics (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Bluebird Bio (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Bristol Myers Squibb (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Sangamo Therapeutics (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Emmaus Life Sciences (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Eli Lilly and Company (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Modus Therapeutics (Sweden)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Gamida Cell (Israel)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Lonza Group (Switzerland)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Addmedica (France)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Selexys Pharmaceuticals (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • GlycoMimetics (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Mast Therapeutics (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Acceleron Pharma (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Angiocrine Bioscience (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Imara Inc. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • AstraZeneca (UK)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Sanofi (France)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments